1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

CBER Staffing Remains Challenging, But Permanent Virtual Work May Help Offset Expected Retirements

 
• By Kate Rawson

Peter Marks predicts that staffing challenges within CBER can be alleviated by offering employees the flexibility to work remotely – permanently. With important posts in the vaccines office still to be hired, it could be an important incentive.

zoom screen
FDA thinks this screen could be a selling point for potential employees. • Source: Shutterstock

US FDA Center for Biologics Evaluation & Research Director Peter Marks hopes that the option for employees to work remotely from outside the Washington, D.C. area – on a permanent basis, even after the pandemic is over – will help offset what is expected to be increased rate of attrition after the strains of the COVID pandemic.

“One of the things in terms of our hiring priorities that’s been made a little bit easier by COVID-19 is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

Former CBER Director Peter Marks Brings Genetic Medicines Street Cred To Lilly

 
• By Jessica Merrill

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.

New US FDA Program Encouraging Domestic Manufacturing May Be ‘Very Selective’

 
• By Sarah Karlin-Smith

Pharmaceutical manufacturers encouraged the FDA to consider including expansions and modifications of existing US drug facilities in the PreCheck program.

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.

More from Agency Leadership

US FDA Independence Questioned At CDC Oversight Hearing

 
• By Michael McCaughan

A Senate committee is investigating leadership changes at the US Centers for Disease Control and Prevention. While the primary focus is vaccine policy, the first hearing suggested the probe could raise questions about FDA independence.

Evita’s Mifepristone Approval Reignites Abortion Pill Controversy

 
• By Dave Wallace

An FDA approval of Evita Solutions' generic mifepristone 200mg tablets has reignited debate about the abortion pill, which Health and Human Services Secretary Robert F. Kennedy Jr. has indicated will be subject to a safety review.

Pink Sheet Podcast: Government Shutdown’s Impact On US FDA, Pfizer Inks Drug Pricing Deal

 
• By Derrick Gingery, Sarah Karlin-Smith, Cathy Kelly, and Sue Sutter

Pink Sheet reporter and editors discuss the issues that could arise for the FDA as it navigates the government shutdown, as well as the aftershocks of Pfizer’s drug pricing deal with the White House.